Vitiligo pp 381-385 | Cite as

Other Immunosuppressive Regimen

  • Markus BöhmEmail author


As described in  Chap. 2.2.7, there is a large body of data indicating that vitiligo, at least distinct clinical subtypes of it, represents an immune-mediated inflam-matory disease. This concept is further corroborated by those patients who experience beneficial effects from anti-inflammatory and/or immunomodulatory treatment, for example, after therapy with corticosteroids or topical calcineurin inhibitors. In this view, different systemic imunomodulators have been proposed for the treatment of the diffuse form of the disease. Recently, the widely used a new class of immunomodulators in dermatology defined as biologics have been tested in vitiligo in a limited number of patients to assess their therapeutic potential in this disease.


Alopecia Areata Vitiligo Patient Topical Calcineurin Inhibitor Depigmented Skin Active Vitiligo 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Abdallah M, Abdel-Naser MB, Moussa MH et al (2003) Sequential immunohistochemical study of depigmenting and repigmenting minigrafts in vitiligo. Eur J Dermatol 13:548–552PubMedGoogle Scholar
  2. 2.
    al Badri AM, Foulis AK, Todd PM et al (1993) Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. J Pathol 169:203–206PubMedCrossRefGoogle Scholar
  3. 3.
    Anbar TS, Abdel-Rahman AT, Ahmad HM (2007) Vitiligo occurring at site of interferon-alpha 2b injection in a patient with chronic viral hepatitis C: a case report. Clin Exp Dermatol 33:503CrossRefGoogle Scholar
  4. 4.
    Bernstein D, Reddy KR, Jeffers L, Schiff E (1995) Canities and vitiligo complicating interferon therapy for hepatitis C. Am J Gastroenterol 90:1176–1177PubMedGoogle Scholar
  5. 5.
    Birol A, Kisa U, Kurtipek GS et al (2006) Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with non-segmental vitiligo. Int J Dermatol 45:992–993PubMedCrossRefGoogle Scholar
  6. 6.
    Cara CJ, Pena AS, Sans M et al (2004) Reviewing the mechanism of action of thiopurine drugs: towards a new paradig in clinical practice. Med Sci Monit 10:247–254Google Scholar
  7. 7.
    Fernandez-Obregon AC (2008) Clinical management with efalizumab of a patient with psoriasis and comorbid vitiligo. J Drugs Dermatol 7:679–681PubMedGoogle Scholar
  8. 8.
    Gokhale BB (1979) Cyclophosphamide and vitiligo. Int J Dermatol 18:92PubMedGoogle Scholar
  9. 9.
    Gokhale BB, Parakh AP (1983) Cyclophosphamide in viti-ligo. Indian J Dermatol 28:7–10PubMedGoogle Scholar
  10. 10.
    Grimes PE, Morris R, Avaniss-Aghajani E et al (2004) Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 51:52–61PubMedCrossRefGoogle Scholar
  11. 11.
    Mahmoud BH, Hexsel CL, Hamzavi IH (2008) An update on new and emerging options for the treatment of vitiligo. Skin Therapy Lett 13:1–6PubMedGoogle Scholar
  12. 12.
    Martínez-Esparza M, Jiménez-Cervantes C, Solano F et al (1998) Mechanisms of melanogenesis inhibition by tumor necrosis factor-alpha in B16/F10 mouse melanoma cells. Eur J Biochem 255:139–146PubMedCrossRefGoogle Scholar
  13. 13.
    Moretti S, Spallanzani A, Amato L et al (2002) New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 15:87–92PubMedCrossRefGoogle Scholar
  14. 14.
    Radmanesh M, Saedi K (2006) The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat 17:151–153PubMedCrossRefGoogle Scholar
  15. 15.
    Ramírez-Hernández M, Marras C, Martínez-Escribano JA (2005) Infliximab-induced vitiligo. Dermatology 210:79–80PubMedCrossRefGoogle Scholar
  16. 16.
    Rigopoulos D, Gregoriou S, Larios G et al (2007) Etanercept in the treatment of vitiligo. Dermatology 215:84–85PubMedCrossRefGoogle Scholar
  17. 17.
    Simon J-A, Burgos-Vargas R (2008) Vitiligo improvement in a patient with ankylosing spondylitis treated with inflixi-mas. Dermatol 216:234–235CrossRefGoogle Scholar
  18. 18.
    Simsek H, Savas C, Akkiz H, Telatar H (1996) Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection. Dermatology 193:65–66PubMedCrossRefGoogle Scholar
  19. 19.
    Skurkovich B, Skurkovich S (2003) Anti-interferon-gamma antibodies in the treatment of autoimmune diseases. Curr Opin Mol Ther 5:52–57PubMedGoogle Scholar
  20. 20.
    Skurkovich SV, Klinova EG, Eremkina EI, Levina NV (1974) Immunosuppressive effect of an anti-interferon serum. Nature 247:551–552PubMedCrossRefGoogle Scholar
  21. 21.
    Skurkovich S, Skurkovich B, Bellanti JA (1987) A unifying model of the immunoregulatory role of the interferon system: can interferon produce disease in humans? Clin Immunol Immunopathol 43:362–373PubMedCrossRefGoogle Scholar
  22. 22.
    Skurkovich S, Korotky NG, Shaova NM, Skurkovich B (2002) Successful anti-IFN therapy of alopecia, vitiligo, and psoriasis. Clin Immunol 103:S103Google Scholar
  23. 23.
    Skurkovich S, Skurkuvich B (2006) Inhibition of IFN-γ as a method of treatment of various autoimmune diseases, including skin disease. In: Numerof R, Dinarello CA, Asadullah K (eds) Cytokines as potential therapeutic targets for inflam-matory skin diseases. Ernst Schering Research Foundation Workshop 58, Springer, Berlin, pp 1–27Google Scholar
  24. 24.
    Smith DI, Heffernan MP (2008) Vitiligo after the resolution of psoriatic plaques during treatment with adalimumab. J Am Acad Dermatol 58:S50–S51PubMedCrossRefGoogle Scholar
  25. 25.
    Swope VB, Abdel-Malek Z, Kassem LM, Nordlund JJ (1991) Interleukins 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol 96:180–185PubMedCrossRefGoogle Scholar
  26. 26.
    Taffaro M, Pyrsopoulos N, Cedron H et al (2007) Vitiligo improvement in a hepatitis C patient after treatment with PEG-interferon alpha-2a and ribavirin: a case report. Dig Dis Sci 52:3435–3437PubMedCrossRefGoogle Scholar
  27. 27.
    Wakkee M, Assen YJ, Thio HB, Neumann HA (2008) Repigmentation of vitiligo during efalizumab. J Am Acad Dermatol 59:S57–S58PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Department of DermatologyUniversity of MünsterMünsterGermany

Personalised recommendations